Advances in Biomarker-Guided Cancer Immunotherapy: Experts Discuss Clinical Utility and Future Directions

Expert faculty Scott Kopetz, MD, PhD, FACP; Jason N. Rosenbaum, MD; and David R. Spigel, MD, discuss recent advances in biomarkers for cancer immunotherapy including clinical utility and future directions.
Scott Kopetz, MD, PhD, FACP
Jason N. Rosenbaum, MD
David R. Spigel, MD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Released: May 16, 2019 Expiration: May 15, 2020

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Outline the biologic basis for the development of immune checkpoint inhibitors to combat cancer
  • Summarize ongoing research regarding the utility of biomarkers, tumor mutational burden, T-cell functional state, LAG-3, composite biomarkers, or other host factors predictive of response to immune checkpoint inhibitors
  • Compare and contrast the different methodologies and assays for identifying biomarkers of response to immune checkpoint inhibitors in different tumor types and treatment settings
  • Implement best practices for biomarker testing/interpretation of results to guide treatment selection in different tumor types and treatment settings
  • Improve interdisciplinary collaboration/communication to aid in the optimal of selection of patients for cancer immunotherapy


Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley

Supported by educational grants from
Bristol-Myers Squibb
Foundation Medicine, Inc.

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:


Scott Kopetz, MD, PhD, FACP

Associate Professor
Department of Gastrointestinal Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas

Scott Kopetz, MD, PhD, FACP, has disclosed that he has ownership interest in Navire and has received consulting fees from Amal Therapeutics, Amgen, Boehringer Ingelheim, Holy Stone, Lilly, Merck, Navire, Novartis, Roche, and Symphogen.
Jason N. Rosenbaum, MD

Assistant Professor
Department of Pathology and Laboratory Medicine
University of Pennsylvania
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania

Jason N. Rosenbaum, MD, has disclosed that he has received consulting fees from Bayer, Bristol-Myers Squibb, and Genentech.
David R. Spigel, MD

Chief Scientific Officer
Lung Cancer Research Program
Sarah Cannon Research Institute
Nashville, Tennessee

David R. Spigel, MD, has disclosed that he has received consulting fees paid to his institution from AbbVie, Aeglea, Amgen, Armo, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Evelo, Foundation Medicine, Genentech/Roche, GlaxoSmithKline, Illumina, Ipsen, Lilly, Merck, Moderna Therapeutics, Nektar, Novartis, PharmaMar, Pfizer, Precision Oncology, and Takeda and funds for research support paid to his institution from AbbVie, Acerta, Aeglea, Amgen, Astellas, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, CellDex, Clovis, Daiichi Sankyo, EMD Serono, Foundation Medicine, G1 Therapeutics, Genentech/Roche, GlaxoSmithKline, Grail, Ipsen, Lilly, Merck, Millennium, Neon Therapeutics, Nektar, Novartis, OncoGenex, Pfizer, Takeda, Tesaro, and Transgene.


Kristen Rosenthal, PhD

Senior Scientific Director

Kristen Rosenthal, PhD, has no relevant conflicts of interest to report.
Bing-e Xu, PhD

Scientific Director

Bing-E Xu, PhD, has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians, oncologists, and other healthcare and laboratory professionals who care for patients with cancer who are candidates for cancer immunotherapy.


The goal of this activity is to improve the knowledge and competence of participants to apply the latest data, on-going clinical trials, and new biomarkers for treatment with cancer immunotherapy.


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from May 16, 2019, through May 15, 2020:

1. Register online at
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Downloadable slides with expert recommendations on the integration of oncology biosimilars into clinical practice from Clinical Care Options.

Gary H. Lyman, MD, MPH, FASCO, FACP, FRCP Released: April 20, 2020

CME/CE/CPE-certified expert module from CCO: oncology biosimilar fundamentals, regulatory process, FDA approvals, and key trial data in breast and lung cancers

Gary H. Lyman, MD, MPH, FASCO, FACP, FRCP Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: April 20, 2020 Expired: April 19, 2021

Expert commentary from Dr. Jeffrey Crawford on the tally of biosimilars available for cancer care and how their use may affect patient management.

Jeffrey Crawford, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.2 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: January 18, 2019 Expired: January 17, 2020

Expert commentary from Dr. Gary Lyman describing the need for continued education and surveillance as biosimilars enter the market.

Gary H. Lyman, MD, MPH, FASCO, FACP, FRCP Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.2 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: December 18, 2018 Expired: December 17, 2019

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the,, and Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?